Preclinical
[대역어] None
[용어속성] Term
[용어속성] Term
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Article
Published on
Journal: Emerging Microbes & Infections
[Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제,
Journal: Emerging Microbes & Infections
[Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제,
[키워드] acute respiratory syndrome
Beta
Blood
caused
clinically
Concentration
coronavirus
COVID-19
creatine phosphokinase
CT-P63
deaths
declining
Delta
demonstrated
detectable
dose
double-blind
evaluated
groups
healthy volunteer
Immunity
in vitro
in vivo
Infection
Infectious virus
lung
monoclonal
monoclonal antibody
morbidity and mortality
mutated variant
Neutralizing
Neutralizing activity
neutralizing antibody
neutralizing antibody.
omicron
pandemic
parallel-group
participant
peaked
phase
Placebo
placebo-controlled
Preclinical
prevalent
Prophylactic
Randomized
reduced
respiratory tract
Safe
SARS-CoV-2
SARS-CoV-2 variant
SARS-CoV-2 variants of concern
Serious Adverse Events
significantly
single ascending dose
study drug
TEAE
titre
Tolerability
Transgenic mouse
treated
Treatment
treatment-emergent adverse event
vaccination
variants
variants of SARS-CoV-2
wild-type
[DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
[DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
Preclinical efficacy and safety of novel SNAT against SARS-CoV-2 using a hamster model
Article
Published on
Journal: Drug delivery and translational research
[Category] COVID19(2023년), SARS, 치료제,
Journal: Drug delivery and translational research
[Category] COVID19(2023년), SARS, 치료제,
[키워드] acute respiratory syndrome
antioxidant
Antiviral
antiviral drug
Antiviral drug candidate
assays
Body weight loss
coronavirus
COVID-19
demonstrated
Efficacy
Efficacy and safety
Epidemic
fibroblast
global public health
hamsters
Health
Histopathology
human cells
human lung epithelium
IMPROVE
Inhaled
inhaler
LDH
lipid peroxidation
lung
MDA
Nanotechnology
oral swabs
other respiratory virus
pandemic
platform
Preclinical
reduce
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2-infected hamsters
silver nanoparticle
SmaRT
SNAT.
tested
virus load
virus titer
[DOI] 10.1007/s13346-022-01166-x PMC 바로가기
[DOI] 10.1007/s13346-022-01166-x PMC 바로가기
Preclinical safety evaluation and tracing of human mesenchymal stromal cell spheroids following intravenous injection into cynomolgus monkeys
Research article
[키워드] addressed
administration
ambient
Blood
blood vessel
Cell
death
demonstrated
dissociate
Efficacy
feasible
Host
hypoxic condition
injection
intravenous
Intravenous injection
less
lung
Mesenchymal stem cells
mice
Monkey
MSC
MSCs
multiple sclerosis
occurred
Osteoarthritis
physiological change
Preclinical
promote
retention
Safe
Safety
Single Cell
small blood vessel
small vessel
Spheroid
Stress
stromal cell
survival
viability
wound healing
[DOI] 10.1016/j.biomaterials.2022.121759 [Article Type] Research article
[DOI] 10.1016/j.biomaterials.2022.121759 [Article Type] Research article
Preclinical findings: The pharmacological targets and molecular mechanisms of ferulic acid treatment for COVID-19 and osteosarcoma via targeting autophagy
Article
[키워드] 2019 coronavirus disease
activities
acute respiratory disease
applied
autophagy
Bioinformatics analysis
characterized
clinical
coronavirus
COVID-19
deficiency
determine
develop
Effectiveness
Evidence
ferulic acid
Genes
impacted
individuals
MAPK1
mechanism
mechanisms
medication
methodology
molecular docking
molecular docking analysis
molecular mechanism
network pharmacology
number of infected
Ontology
osteosarcoma
pandemic
pathway enrichment
Patient
Patients with cancer
pharmacological
pharmacological target
PIK3R1
Population
potential therapeutic target
Preclinical
Protein
regulatory subunit
SARS-CoV-2
STAT3
target
targets
therapeutic
therapeutic targets
therapeutic targets.
Transcription
treat
treatment for COVID-19
variant
[DOI] 10.3389/fendo.2022.971687 PMC 바로가기
[DOI] 10.3389/fendo.2022.971687 PMC 바로가기
Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
Article
[키워드] acute respiratory syndrome
amino acid substitution
amubarvimab (BRII-196)
antibody
antibody cocktail
Clinical efficacy
Combination
controls
coronavirus
coronavirus disease
COVID-19
demonstrated
Emergency use authorization
epitope
EUA
Evolution
half-maximal inhibitory concentration
half-maximal inhibitory concentration (IC50)
in vitro
introduced
less
Lung pathology
Lungs
M252Y/S254T/T256E (YTE)
mAb
mAbs
Modification
monoclonal antibody
monoclonal antibody (mAb)
Mutation
neutralize
neutralized
Neutralizing
Post-infection
Preclinical
RBD
receiving
Receptor binding domain
receptor binding domain (RBD)
reduce
reduced
regions
regulatory authority
resulting
retained
romlusevimab (BRII-198)
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 variants
serum
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
significantly
Spike protein
Support
susceptibility
therapeutic option
variant
Variant of concern (VOC).
variants
variants of concern
Viral load
virus
virus
VoC
weight loss
[DOI] 10.3389/fimmu.2022.980435 PMC 바로가기
[DOI] 10.3389/fimmu.2022.980435 PMC 바로가기
Influence of Effort-based Reward Training on Neuroadaptive Cognitive Responses: Implications for Preclinical Behavioral Approaches for Depressive Symptoms
Research article
[키워드] approach
approaches
assigned
BDNF
brain-derived neurotrophic factor (BDNF)
cognitive
Dehydroepiandrosterone (DHEA)
depressive
depressive symptom
Depressive symptoms
disorder
Efficacy
Effort-based Reward (EBR)
examination
exhibited
faster
female
group
immunoreactivity
incidence rate
influence
lack
Lateral habenula (LHb)
male
males
mechanism
mechanisms
no significant effect
offer
Preclinical
Preclinical model of depression
prevented
provide
response
therapeutic intervention
Therapies
training
Trial
trials
were assessed
[DOI] 10.1016/j.neuroscience.2022.08.002 [Article Type] Research article
[DOI] 10.1016/j.neuroscience.2022.08.002 [Article Type] Research article
Cell-Based Platform for Antigen Testing and Its Application for SARS-CoV-2 Infection
Article
[키워드] active infection
acute respiratory syndrome
amplification
Antigen
antigen test
applicability
application
asymptomatic individual
Calu-3
can be used
CAR
CAR T-cell
Care
Cell
cell line
cell-based sensors
characterized
Community
competent
conducted
control sample
coronavirus
COVID-19
COVID-19 diagnostics
detect
diagnosing
effective
facilitate
function
Health
host cell
implementation
individual
infected with SARS-CoV-2
Infection
infections
lack
mice
molecular
mRNA
offer
oropharyngeal swab
pandemic
Pandemics
PCR
platform
Preclinical
present antigen
qPCR
quantitative PCR
reporter
reporter cell.
robust
SARS-CoV-2
Signaling
specificity
spike glycoprotein
symptomatic
target pathogen
tested
Testing
viruses
Volume
[DOI] 10.1128/spectrum.00731-22 PMC 바로가기
[DOI] 10.1128/spectrum.00731-22 PMC 바로가기
Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy
Review article
[키워드] ACE2angiotensin converting enzyme 2
acute lung injury
acute respiratory distress syndrome
adverse outcome
ALIacute lung injury
alveolar type 2 cells
angiotensin converting enzyme 2
ARDSacute respiratory distress syndrome
AstraZeneca
AT2salveolar type 2 cells
ataxia telangiectasia and Rad3-related
ATRataxia telangiectasia and Rad3-related
BDNFbrain derived neurotrophic factor
brain derived neurotrophic factor
BRDbromodomain protein
bromodomain protein
C-reactive protein
CCNG1Cyclin G1
CD147cluster of differentiation 147
Cell
Clinical finding
cluster of differentiation 147
confirmed case
Coronavirus disease 2019
COVID-19
COVID-19 pandemic
COVID-19 patients
COVID-19coronavirus disease 2019
CRPC-reactive protein
Cyclin G1
Cytokine storm
DRP1dynamin-related protein 1
dynamin-related protein 1
ECMOextracorporeal membrane oxygenation
effective
EGFepidermal growth factor
Emergency use authorization
epidermal growth factor
EUAemergency use authorization
EVsextracellular vesicles
example
exhibited
Extracellular vesicles
extracorporeal membrane oxygenation
FGFfibroblast growth factor
fibroblast growth factor
galanin and gmap prepropeptide
GALgalanin and gmap prepropeptide
GM-CSFgranulocyte macrophage-colony stimulating factor
granulocyte macrophage-colony stimulating factor
HBVHepatitis B virus
Heme oxygenase-1
Hepatitis B virus
hepatocyte growth factor
hESCshuman embryonic stem cells
HGFhepatocyte growth factor
hiPSCshuman induced PSCs
HIVhuman immunodeficiency virus
HO-1heme oxygenase-1
hPSC-CMshPSC-derived cardiomyocytes
hPSC-derived cardiomyocytes
hPSCshuman pluripotent stem cells
human embryonic stem cells
Human immunodeficiency virus
human induced PSCs
human pluripotent stem cells
Hyperinflammatory syndrome
IFN-βinterferon-β
IFN-γinterferon-γ
IFN-λinterferon-λ
IGF1Rinsulin like growth factor 1 receptor
Infection
insulin like growth factor 1 receptor
Intensive
Interferon-β
interferon-γ
interferon-λ
keratinocyte growth factor-2
KGF2keratinocyte growth factor-2
leukemia inhibitory factor
LIFleukemia inhibitory factor
management
MECP2methyl-CpG binding protein 2
Mesenchymal stem cells
methyl-CpG binding protein 2
Microvesicles
Moderna
Mortality
MSCs
MSCs therapy
MSCsmesenchymal stem cells
MVsmicrovesicles
National Institutes of Health
nerve growth factor
NGFnerve growth factor
NIHNational Institutes of Health
nitric oxide associated 1
NLR family pyrin domain containing 3
NLRP3NLR family pyrin domain containing 3
NOA1nitric oxide associated 1
organ damage
organ injury
P4HA1prolyl 4-hydroxylase subunit alpha 1
PDGFplatelet-derived growth factor
Pfizer
PGE2prostaglandin E2
phosphatase and tensin homolog
platelet-derived growth factor
Preclinical
Preferred reporting items for systematic reviews and meta-analyses
PRISMAPreferred reporting items for systematic reviews and meta-analyses
proinflammatory
prolyl 4-hydroxylase subunit alpha 1
prostaglandin E2
PTENphosphatase and tensin homolog
Pulmonary infection
Randomized controlled trial
RCTrandomized controlled trial
S-proteinspike protein
SARS-CoV-2severe acute respiratory syndrome coronavirus 2
SEMA3Asemaphorin 3 A
semaphorin 3 A
severe acute respiratory syndrome coronavirus 2
sialyl Lewis X
signal transducer and activator of transcription 3
SLeXsialyl Lewis X
Spike protein
spread of COVID-19
STAT3signal transducer and activator of transcription 3
stem cell
TGF-β1transforming growth factor β1
TGFBR1transforming growth factor β receptor I
Therapies
therapy
tissue regeneration
TLR4toll-like receptors 4
TMPRSS2transmembrane protease serine protease 2
TNFTumor Necrosis Factor
toll-like receptors 4
transforming growth factor β receptor I
transforming growth factor β1
transmembrane protease serine protease 2
tumor necrosis factor
utility
Vaccine
Vaccines
vascular cell adhesion molecule
vascular endothelial growth factor
VCAMvascular cell adhesion molecule
VEGFvascular endothelial growth factor
[DOI] 10.1016/j.phrs.2022.106334 [Article Type] Review article
[DOI] 10.1016/j.phrs.2022.106334 [Article Type] Review article
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera
수포성 구내염 바이러스-SARS-CoV-2 키메라 기반 코로나19 후보 백신의 전임상 면역원성과 효능
Article
[키워드] acute respiratory syndrome
administration
AIDS
approach
authority
candidate vaccine
chimeric
coding sequence
coronavirus
coronavirus disease
cotton
Cotton rat
COVID-19
COVID-19 vaccine
Department
develop
development
dose
Ebola virus
Efficacy
evaluated
glycoprotein
hamster
hamsters
Immunity
immunogenic
immunogenicity
Inc
Inc.
initiative
injection
intramuscular
lung
mucosal
Mucosal vaccination
nasal
nasal tissue
New York
Part
Preclinical
PROTECT
reduce
reduced
replacing
Research
respond
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 replication
SARS-CoV-2 vaccine
Sharp
significantly
single vaccine
spike
stomatitis
supported
Syrian hamster
the SARS-CoV-2
the vaccine
threat
tissues
Transmission
USA
vaccination
Vaccine
vaccine candidate
vesicular stomatitis
vesicular stomatitis virus
Vesicular stomatitis virus.
virus
virus load
VSV
weight loss
[DOI] 10.1016/j.ebiom.2022.104203 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.ebiom.2022.104203 PMC 바로가기 [Article Type] Article